COVID-19 transport and travel risks insights
Kennedys experts explore how COVID-19 is impacting on transport and travel.
From To
Subscribe to our latest updates, reports and events.
SubscribeShowing 1 - 10 of 26
Sort by
-
Article 19/05/2022
Managing unavoidable and extraordinary circumstances
In the wake of COVID-19, what is considered as unavoidable and extraordinary circumstances (UECs) has become simultaneously more relevant and less clear. In this article, we delve into what situations are likely to meet the threshold of UECs in the context of COVID-19, what customers’ rights are in these circumstances and what travel companies can do to help.
-
Article 22/02/2022
Shipping in the UAE: latest developments and topics to watch
The United Arab Emirates continues to be a critical hub for global shipping. It, like all other major centres for maritime trade, has had to respond to significant changes and disruption in recent years. Here we highlight some of the key developments in the region for both insurers and their insureds now recovery from the pandemic is well underway.
-
Article 13/09/2021
E-scooters present challenges for our liability framework
New technologies bring both opportunity and risk, the balance of which is most often finely balanced. Success or otherwise is largely dependent on the impact on the particular ‘ecosystem’ in which that technology will operate.
-
Article 06/05/2021
Protect Duty consultation: protecting public places from terrorist attacks
On 26 February 2021, the Home Office launched a consultation into how the Government might use legislation to improve protective security and organisational preparedness at publicly accessible locations across the UK. The consultation seeks views from anyone who might be affected by a new “Protect Duty”, from individuals to businesses and public authorities. The consultation closes on 2 July 2021.
-
Article 30/04/2021
International travel arrangements - impact on the travel industry
As the vaccination effort gains momentum, UK Government ministers are already setting targets for overseas travel. To date, over 30 million people in the UK have received the first dose of the vaccination resulting in calls for a ‘vaccine passport’ (or ‘COVID health certificate’), among others, to be implemented giving the travel industry a chance to begin its recovery process.
-
Article 22/03/2021
Europe’s cannabis products regulatory regime: evergreen or erratic? Part 1: Food products
For some time, the regulatory framework applicable to cannabis products in Europe has been widely recognised as being particularly complex. As a result of this, companies frequently struggle with successfully navigating the regulatory regimes applicable in each country in which they sell. This looks set to continue as new UK requirements come into force on 1 April 2021.
-
Article 08/03/2021
The direction of travel in 2021
The COVID-19 pandemic and Brexit have brought many challenges and changes to the way travel organisers have planned and operated their businesses over the past 12 months. Whilst the Brexit deadline for a deal has been and gone, its effects are still very much with us as businesses now need to work through the ramifications of the Trade and Cooperation Agreement (TCA) on their UK and overseas operations.
-
Article 03/03/2021
London marine market forecast 2021
2021 promises to be a year dominated by evolution, transformation, and resilience. In this article we identify some of the key areas and issues that will have an impact upon the London marine market in 2021.
-
Report 06/01/2021
COVID-19: what will it mean for the future of risk?
Our research identified five key risk themes that have implications and represent both challenges and opportunities for businesses, insurers, and wider society. This will assist in moving the conversation forward as we look beyond COVID-19, highlighting the important need to reshape the dynamic relationship between companies, households, and insurers.
-
Article 05/01/2021
COVID-19 vaccines – bringing hope to many, but presenting challenges to forwarders
In early December 2020, the UK government announced with considerable fanfare its approval of Pfizer/BioNTech’s COVID-19 vaccine. Around 40 million doses were ordered, and the UK’s mass vaccination programme commenced in December 2020, with the US, Canada, Bahrain and Saudi Arabia close behind. On 30 December 2020, the Oxford AstraZeneca vaccine received UK approval with the first doses administered in early January.